Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Treasury Shares: 2016-2024

Historic Treasury Shares for UroGen Pharma (URGN) over the last 9 years, with Dec 2024 value amounting to $1.5 million.

  • UroGen Pharma's Treasury Shares rose 37.24% to $1.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.5 million, marking a year-over-year increase of 37.24%. This contributed to the annual value of $1.5 million for FY2024, which is 37.24% up from last year.
  • Per UroGen Pharma's latest filing, its Treasury Shares stood at $1.5 million for FY2024, which was up 37.24% from $1.1 million recorded in FY2023.
  • UroGen Pharma's Treasury Shares' 5-year high stood at $1.5 million during FY2024, with a 5-year trough of $690,955 in FY2022.
  • Moreover, its 3-year median value for Treasury Shares was $1.1 million (2023), whereas its average is $1.1 million.
  • As far as peak fluctuations go, UroGen Pharma's Treasury Shares fell by 8.27% in 2022, and later skyrocketed by 59.01% in 2023.
  • Yearly analysis of 5 years shows UroGen Pharma's Treasury Shares stood at $720,416 in 2020, then grew by 4.56% to $753,274 in 2021, then decreased by 8.27% to $690,955 in 2022, then skyrocketed by 59.01% to $1.1 million in 2023, then surged by 37.24% to $1.5 million in 2024.